Case studies for implementing MCDA for tender and purchasing decisions in hospitals in Indonesia and Thailand

References

• Maniadakis N, Kourlaba G, Shen J, Holtorf A. Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status. BMC Health Serv Res. 2017;17(1):371.
   PubMedGoogle Scholar
• Johnston A, Holt DW. Substandard drugs: a potential crisis for public health. Br J Clin Pharmacol. 2014;78(2):218–243.
   PubMed Web of Science ®Google Scholar
• Rinaldi F, de Denus S, Nguyen A, Nattel S, Bussières J-F. Drug shortages: patients and health care providers are all drawing the short straw. Can J Cardiol. 2017;33(2):283–286.
   PubMed Web of Science ®Google Scholar
• Nakakeeto ON, Elliott BV. Antiretrovirals for low income countries: an analysis of the commercial viability of a highly competitive market. Glob Health. 2013;9(1):6.
   PubMedGoogle Scholar
• Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making—an introduction: report 1 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1–13.
   PubMed Web of Science ®Google Scholar
• Brixner D, Maniadakis N, Kaló Z, Hu S, Shen J, Wijaya K. Considering multicriteria decision analysis (MCDA) simple scoring as an evidence-based HTA methodology for evaluating off-patent pharmaceuticals (OPPs) in emerging markets. Value Health Reg Issues. 2017;13:1–6.
   PubMedGoogle Scholar
• Kaló Z, Holtorf A-P, Alfonso-Cristancho R, Shen J, Ágh T, Inotai A, et al. Need for multicriteria evaluation of generic drug policies. Value Health. 2015;18(2):346–351.
   PubMed Web of Science ®Google Scholar
• Keeney RL, Raiffa H. Decisions with multiple objectives: preferences and value trade-offs. Cambridge: Cambridge University Press; 1993. p. 596.
   Google Scholar
• Inotai A, Brixner D, Maniadakis N, Dwiprahasto I, Kristin E, Prabowo A, et al. Development of multi-criteria analysis (MCDA) framework for off-patent pharmaceuticals—an application on improving tender decision making in Indonesia. BMS Health Serv Res. 2018. https://doi.org/10.1186/s12913-018-3805-3.
   PubMed Web of Science ®Google Scholar
• Nurgozhin T, Nurtaev A, Maniadakis M. Development of multiple criteria decision analysis framework for off-patent-pharmaceuticals procurement in SK_Pharmacia Kazakhstan. Meditsina Almaty. 2018;2(188):2–13. https://doi.org/10.31082/1728-452X-2018-188-2-22-33.
   Google Scholar
• Abdullah AH, Holtorf A-P, Al-Hussaini M, Lemay J, Alowayesh M, Kaló Z. Stakeholder driven development of a multi-criteria decision analysis tool for purchasing off-patent pharmaceuticals in Kuwait. J Pharm Policy Pract. 2019;12(1):9.
   PubMed Web of Science ®Google Scholar
• Assawamakin A, Holtorf A-P, Maniadakis N. Weighing price and performance for decisions for multisource pharmaceutical bidding in public hospitals in Thailand. In: Reddy S, editor. Evaluation of Health Programs. London: INTECH Open Access Publisher; 2019. p. 14.
   Google Scholar
• Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, et al. Guidance towards the implementation of multi-criteria decision analysis framework in developing countries. Expert Rev Pharmacoecon Outcomes Res. 2018;18(6):585–592. https://doi.org/10.1080/14737167.2018.1508345.
   PubMed Web of Science ®Google Scholar
• Kristin E, Bustami M. Workshop on multi-criteria decision analysis (MCDA) in decision-making related to off-patent pharmaceuticals (OPP). Indonesia: University of Gadjah Mada; 2021. in submission
   Google Scholar
• Upakdee N, Assamawakin A, Promprasert V, Chungsivapornpong W, Sumitsawan J, Ratanachompoo C, et al. The application price performance for the procurement of government drugs with multiple vendors: case studies in pilot hospitals. Bangkok: The Pharmaceutical Association of Thailand under Royal Patronage; 2020.
   Google Scholar
• Schreier M. Qualitative content analysis in practice. Los Angeles: SAGE; 2012. p. 284.
   Google Scholar
• Neuendorf KA. The content analysis guidebook. Los Angeles: SAGE Publications; 2016. p. 457.
   Google Scholar
• Chapman AL, Hadfield M, Chapman CJ. Qualitative research in healthcare: an introduction to grounded theory using thematic analysis. J R Coll Physicians Edinb. 2015;45(3):201–205.
   PubMed Web of Science ®Google Scholar
• Corbin J, Strauss A. Basics of qualitative research: techniques and procedures for developing grounded theory. 4th ed. Los Angeles: SAGE Publications Inc; 2014. p. 456.
   Google Scholar
• Drake JI, de Hart JCT, Monleón C, Toro W, Valentim J. Utilization of multiple-criteria decision analysis (MCDA) to support healthcare decision-making FIFARMA, 2016. J Mark Access Health Policy. 2017;5(1):1360545.
   PubMedGoogle Scholar
• Poudel A, Nissen LM. Rational and responsible medicines use (Chapter 16). In: Ibrahim MIM, Wertheimer AI, Babar ZUD, editors. Social and administrative aspects of pharmacy in low-and middle-income countries. Cambridge: Academic Press; 2018. p. 263–277. (10.1016/B978-0-12-811228-1.00016-9).
   Google Scholar
• Baltussen R, Marsh K, Thokala P, Diaby V, Castro H, Cleemput I, et al. Multicriteria decision analysis to support health technology assessment agencies: benefits, limitations, and the way forward. Value Health. 2019;22(11):1283–1288. https://doi.org/10.1016/j.jval.2019.06.014.
   PubMed Web of Science ®Google Scholar
• Bakhtiari A, Takian A, Majdzadeh R, Haghdoost AA. Assessment and prioritization of the WHO “best buys” and other recommended interventions for the prevention and control of non-communicable diseases in Iran. BMC Public Health. 2020;20(1):333.
   PubMed Web of Science ®Google Scholar
• Espinoza MA, Rojas R, de Acosta Patiño H. Knowledge translation in practice: exploring the potential use of MCDA in central America and the Caribbean. Value Health Reg Issues. 2018;17:148–149.
   PubMedGoogle Scholar
• Hu S, Zhang Y, He J, Du L, Xu M, Xie C, et al. A case study of pharmaceutical pricing in china: setting the price for off-patent originators. Appl Health Econ Health Policy. 2015;13(1):13–20. https://doi.org/10.1007/s40258-014-0150-5.
   Web of Science ®Google Scholar
• Al-Badriyeh D, Alabbadi I, Fahey M, Al-Khal A, Zaidan M. Multi-indication pharmacotherapeutic multicriteria decision analytic model for the comparative formulary inclusion of proton pump inhibitors in Qatar. Clin Ther. 2016;38(5):1158–1173.
   PubMed Web of Science ®Google Scholar
• Marsh K, Ijzerman M, Thokala P, Baltussen R, Boysen M, Kalo Z, et al. Multiple criteria decision analysis for health care decision making—emerging good practices: report 2 of the ISPOR MCDA emerging good practices task force. Value Health. 2016;19(1):1–13.
   PubMed Web of Science ®Google Scholar
• Lasalvia P, Prieto-Pinto L, Moreno M, Castrillón J, Romano G, Garzón-Orjuela N, et al. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review. Expert Rev Pharmacoecon Outcomes Res. 2019;19(4):409–420.
   PubMed Web of Science ®Google Scholar
• Laba T-L, Jiwani B, Crossland R, Mitton C. Can multi-criteria decision analysis (MCDA) be implemented into real-world drug decision-making processes? A Canadian provincial experience. Int J Technol Assess Health Care. 2020;36:434–439. https://doi.org/10.1017/S0266462320000525.
   Web of Science ®Google Scholar
• Diaby V, Goeree R, Hoch J, Siebert U. Multi-criteria decision analysis for health technology assessment in Canada: insights from an expert panel discussion. Expert Rev Pharmacoecon Outcomes Res. 2015;15(1):13–19.
   PubMed Web of Science ®Google Scholar
• Szulanski G. The process of knowledge transfer: a diachronic analysis of stickiness. Organ Behav Hum Decis Process. 2000;82(1):9–27.
   Web of Science ®Google Scholar
• Elwyn G, Taubert M, Kowalczuk J. Sticky knowledge: a possible model for investigating implementation in healthcare contexts. Implement Sci. 2007;2(1):44.
   PubMedGoogle Scholar
• Marsh KD, Sculpher M, Caro JJ, Tervonen T. The use of MCDA in HTA: great potential, but more effort needed. Value Health. 2018;21(4):394–397.
   PubMed Web of Science ®Google Scholar
• Brixner D, Maniadakis N, Kaló Z, Kim K, Wijaya K. An evidence framework for off-patent pharmaceutical review (EFOR) for health technology assessment in emerging markets. Value Health Reg Issues. 2018;16c:9–13.
   Google Scholar
• Kotter JP. Leading Change: Why Transformation Efforts Fail. Harvard Business Review [Internet]. 1995. https://hbr.org/1995/05/leading-change-why-transformation-efforts-fail-2. Accessed 30 Sep 2020.
   Google Scholar
• Kotter JP. Accelerate! Harvard Business Review [Internet]. 2012. https://hbr.org/2012/11/accelerate. Accessed 30 Sep 2020.
   Google Scholar
• Smith N, Hall W, Mitton C, Bryan S, Urquhart B. What constitutes high performance in priority setting and resource allocation? Decision maker narratives identified from a survey and qualitative study in Canadian healthcare organizations. Health Serv Manage Res. 2014. https://doi.org/10.1177/0951484814559714.
   PubMedGoogle Scholar